Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial
The National Key Research and Development Program of China, the National Science and Technology Major Projects, the National Natural Science Foundation of China, the Young Science and Technology Talent Support Program of Guangdong Precision Medicine Application Association, and Capital's Funds for Health Improvement and Research.
Authors
- Feifei Sun (ORCID: https://orcid.org/0000-0001-9539-1451)
- Suying Lü (ORCID: https://orcid.org/0000-0001-8117-3533)
- Ruiqing Cai (ORCID: https://orcid.org/0009-0000-4343-7868)
- Jia Zhu
- Zijun Zhen (ORCID: https://orcid.org/0000-0002-4442-0897)
- Yizhuo Zhang (ORCID: https://orcid.org/0000-0002-6128-3476)
- Xueting Yao
- Yi Que
- Jing Zhan (ORCID: https://orcid.org/0000-0002-1845-4604)
- Juan Wang (ORCID: https://orcid.org/0000-0002-3105-3725)
- Dongyang Liu (ORCID: https://orcid.org/0000-0002-0608-8192)
- Junting Huang
- Liting Deng
- Shixing Zhu (ORCID: https://orcid.org/0009-0005-5626-6574)
- Xin Wang (ORCID: https://orcid.org/0000-0002-3561-3160)
Institutions
- Sun Yat-sen University (CN)
- China Pharmaceutical University (CN)
- Peking University (CN)
- Peking University Third Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-05-23
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103258
- Citations
- 2
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 2.09